Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zila Pharm IncfiledCriticalZila Pharm Inc
Publication of GR900100554ApublicationCriticalpatent/GR900100554A/en
Publication of GR1001331BpublicationCriticalpatent/GR1001331B/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
The use of hydroxypropyl cellulose for the production of membrane formation compositions for in situ treatment of human tissue injuries, bacterial and fungal infections, where the composition includes: a) hydroxypropyl cellulose, b) an esterification factor which reacts with hydroxypropyl cellulose to form a reaction product which is soluble in the solvent of paragraph (c), though it is insoluble in body fluids and body temperatures, c) a non-toxic, volatile solvent for the said hydroxypropyl cellulose and the said reaction product. The esterification factor is preferably a weak organic acid, and more preferably a salicylic acid or a mixture of salicylic and tannic acids. The composition can also include boric acid and/or a separate medical component.
GR900100554A1990-07-181990-07-18Compositions and in situ methods for forming films on body tissue
GR1001331B
(en)
Divalent metal salts of 2-N, N-di (cararboxymethyl) amino-3-cyano-4-carboxymethyl-5-thiophenecarboxylic acid, process for its preparation and these containing pharmaceutical preparations.
Adjuvant for promoting absorption of therapeutically active substances through the digestive tract, pharmaceutical composition comprising said adjuvant and process for preparing said pharmaceutical composition; enamine derivatives
OPTICALLY ACTIVE PRODUCTS OF 20,21DINOREBUNAMENINE DERIVATIVES, METHOD OF MANUFACTURE, THEIR USE AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.